‘Brexit Budget’ must not further delay new medicines for patients, says IPHA

The Irish Pharmaceutical Healthcare Association (IPHA) has said the ‘Brexit budget’ announced today [Tuesday] must not further delay the Health Service Executive’s approval of new medicines, causing standards of care for patients to fall relative to European countries.

IPHA, which represents the originator biopharmaceutical industry, called for an ‘adequate allocation for new medicines’ as the Government announced an extra €1 billion in health spending.